Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158 · cited 1×
“All individuals fulfilled the following inclusion criteria: (1) no significant alcohol consumption (the definition of significant alcohol consumption has been inconsistent and ranged from 41 alcoholic beverage (10 g of alcohol per one drink unit) per day to 440 g per day); (2) no significant acute or chronic inflammat…”
BackgroundKanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Brown and beige fat: Development, function and therapeutic potential
Harms, M., & Seale, P. (2013) · Nature Medicine · doi:10.1038/nm.3361 · Cited by 2,328
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Cited by
Items 501–566 of 566
The gut microbiota-bile acid-FXR axis in NAFLD: from progression to therapeutic applications
Zheng, W., Feng, Q., Wang, J., Li, X. X., & Yin, S. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1811118 · Cited by 1
“…fi cally, inhibition of intestinal FXR signaling by glycine-b -muricholic acid (G-b -MCA) prevents high-fat diet (HFD)-induced obesity, insulin resistance, and hepatic steatosis in mice (Jiang et al., 2015), further con fi rming the tissue-speci fi c regulatory role of FXR in metabolic homeostasis.”
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1881697 · Cited by 2
Immunomodulatory mechanisms of bile acids in autoimmune diseases along the gut-liver axis
Zhang, S., Xiong, X., Wei, S., Meng, R., An, H., & Chen, L. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104183 · Cited by 1
Bisson, W. H., Amedei, A., Memeo, L., Forte, S., & Felsher, D. W. (2017) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781119023647.ch14 · Cited by 2
Self-citationRecent advances in understanding cross-talk between Bile Acids and Gut Microbiota
Feng, C. C., Zhang, A. H., Miao, J., Sun, H., Han, Y., Gl, Y. G., Wu, F. F., & Wang, X. (2018) · Open Journal of Proteomics and Genomics · doi:10.17352/ojpg.000007 · Cited by 2
Verdauungsoptimierung – wie sich Ernährung und Mikrobiom gegenseitig beeinflussen
Bischoff, S. C. (2020) · Aktuelle Ernährungsmedizin · doi:10.1055/a-1295-6604 · Cited by 1
“Farneosid-X-Rezeptor (FXR)-Inhibitoren zur Behandlung dieser Pathologie erfolgreich untersucht wurden [19].”
BackgroundRole of gut microbiota in the pathogenesis of type 2 diabetes mellitus (literature review)
Koval, S. M., & Snihurska, I. O. (2021) · Medicni perspektivi · doi:10.26641/2307-0404.2021.4.248064 · Cited by 2
Mechanisms: Xenobiotic Receptor-Mediated Toxicity
Perdew, G. H., Murray, I. A., Patterson, A. D., & Peters, J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64105-3 · Cited by 1
Self-citationLallement, J., Raho, I., Merlen, G., Rainteau, D. P., Croyal, M., Schiffano, M., Kassis, N., Doignon, I., Soty, M., Lachkar, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.16.460588 · Cited by 1
La acuicultura en México, bases conceptuales y principios
Gutiérrez, M. R., & Jiménez, C. M. (1996) · Oceanologia · Cited by 1
Early-life Microbiome-Derived HCA Enhances Type 3 Immunity via FXR- dependent m 6 A RNA methylationPreprint
Yang, Z., Lin, Z., You, Y., Zhang, M., Gao, N., Wang, X., Peng, J., & Wei, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.04.602137 · Cited by 1
Gut microbial regulation of bile acid metabolism and signaling
Sayin, S. I. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Kobal, P. S. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-05062017-164430 · Cited by 2
Blutzuckersenkung durch den Phosphatbinder Sevelamer
KAHL, S. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0328-9
“Dieser Effekt wurde mit einer verminderten Biosynthese von Zeramiden intestinalen Ursprungs in Verbindung gebracht, welche dieThermogenese des beigen Fettgewebes beeinträchtigen [5].”
BackgroundDevelopment of antibacterial compounds that block evolutionary pathways to resistancePreprint
Zhang, Y., Chowdhury, S., Rodrigues, J. V., & Shakhnovich, E. I. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.30.362582
Chiang, J. Y. L. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727333300.793538896
Aguilar-Salinas, C. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733866855.793558330
Role of sphingolipids in inflammatory carciongensis
El-Hindi, K. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.71949
Pathophysiology of Bile Acid Regulation
Sujka, J. A., & DuCoin, C. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-25828-2_7
Wang, L., Gao, C. Y., Wang, C., & Wang, B. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4533760
Mechanisms: Xenobiotic Receptor-Mediated Toxicity
Perdew, G. H., Murray, I. A., Patterson, A. D., & Peters, J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00034-6
Self-citationBile Acids and Gestational Diabetes Mellitus: Exploring the Link and ImplicationsPreprint
Lu, C., Gao, Z., & Lei, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4869474
Mai, L., Su, Y., Liu, B., Sun, X., Li, Z., Shi, Y., Nørgaard, J. V., Liang, H., Li, J., Li, W., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5251663
Self-citationWang, H., Hou, L., Chen, X., Gui, L., Jiang, W., & Tang, W. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106798
Microbiome, dysbiosis and use of probiotics in various diseases
Önata, E. T., & Özdemır, Ö. (2025) · World Journal of Virology · doi:10.5501/wjv.v14.i2.99574 · Cited by 3
Effect of Sevelamer versus Bifidobacterium longum on Insulin Sensitivity in Subjects with ObesityPreprint
Baeuerle, E., Semwal, M. K., Nie, J., Zhang, N., Liang, H., Ganapathy, V., Sathavarodom, N., Fernandez, R. A., Wang, C.-P., Espinoza, S. E., et al. (2025) · medRxiv · doi:10.1101/2025.06.23.25327556
Wen, Y. U., ZHANG, C., Xiao, J., Song, H., XIONG, L., Wang, L., Shen, X., & Wang, F. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0181
The Investigation into Correlation between Type 2 Diabetes Mellitus and the Gut Microbiota
Liu, S., & Zhu, A. M. (2025) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2025.1511022
Liu, Y., Zhong, X., Lin, S., Xu, H., Liang, X., Wang, Y., Xu, J., Wang, K., Guo, X., Wang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603925
Self-citationMünzker, J., Haase, N., Till, A., Sucher, R., Haange, S.-B., Nemetschke, L., Gnad, T., Jäger, E., Chen, J., Riede, S. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20138364
Liu, Y., Zhong, X., Lin, S., Xu, H., Liang, X., Wang, Y., Xu, J., Wang, K., Guo, X., Wang, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603919
Self-citationTian, L., Lin, Y., Yue, P., Gao, L., Wang, L., Huang, C., Zhao, J., Jiang, N., Xi, J., Ma, H., et al. (2026) · iMetaMed · doi:10.1002/imm3.70029 · Cited by 1
Self-citationYu, S.-R., Sun, R., Shi, M.-Y., Yang, M., Chen, K., Pan, Q., Zhao, L., Wu, M.-Y., & Chai, J. (2026) · Liver Research · doi:10.1016/j.livres.2026.02.001
“69,77,78 Conversely, it has also been demonstrated both in vivo and in vitro that intestinal FXR activation attenuates IBD progression by restraining pro-inflammatory lymphocyte infiltration and cytokine production.”
Yu, X., Zhu, M., Wang, K., Yuan, B., Lu, Y., Li, S., & Hu, F. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108532
Role of environmental factors on intestinal barrier dysfunctions reported in obesity
Postal, B. G. (2019) · theses.fr (ABES) · doi:10.70675/4b9e7a12ze552z46bez8767z3241d10852d3
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Salduz, Z. İ. Y., Turgut, R., Coskun, Z. S., Pasin, O., Kartal, M., & Özder, A. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02231-z
“The sample size was determined by power analysis, which indicated that at least 52 participants were needed to detect the expected effect size (assuming a correlation coefficient of 0.38, a 95% confidence level, and 80% statistical power) [18].”
InfluentialHe, Y., Tan, J., Liu, J., Zhong, R., Jiang, L., & Zhao, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108288 · Cited by 2
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
“Dysregulated bile acid signaling in MASLD has been linked to altered lipid metabolism, oxidative stress, and inflammatory activation [123,124,125].”
Zhang, N., Ye, X., Wang, K., Hu, Y., Wang, Z., Huang, L., Chen, X., Yan, D., Fu, W., Xue, Q., et al. (2026) · Cell Discovery · doi:10.1038/s41421-026-00904-6
“The physiological context of these fi ndings aligns with emerging evidence that intestinal FXR inhibition exerts metabolic bene fi ts 38,39,49 – 52 .”
Liu, H., Li, H., Zhai, Y., Zhang, F., Huang, J., Sun, J., Lyu, Y., & Huang, M. (2026) · Food Chemistry X · doi:10.1016/j.fochx.2026.104244
“Although FXR exerts divergent effects on glucose metabolism depending on physiological context (Jiang et al., 2015), intestinal FXR activation induces FGF15 expression, which suppresses hepatic gluconeogenesis and promotes glycogen synthesis (Kir et al., 2011; Potthoff et al., 2011).”
Pulsatile FXR activation: Timing bile acid-targeted therapy to physiology
Jiao, T., Li, Y.-T., Gonzalez, F. J., & Xie, C. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01889-4
“Glycine-β -muricholic acid (Gly-MCA), derived from the natural FXR antagonist tauro-β -muricholic acid, suppresses intestinal FXR signaling, reduces ceramide biosynthesis, and improves glucose and lipid metabolism, hepatic steatosis, in fl ammation, and fi brosis in metabolic disease models [26, 30].”
Self-citationAlexiev, A., Stagaman, K., Kasschau, K. D., Zhang, Y., Raber, J., Gombart, A. F., Maier, C. S., Stevens, J. F., & Sharpton, T. J. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1886058
“FXR regulates hepatic and intestinal lipid and bile acid metabolism pathways (Chen et al., 2024; Fleishman and Kumar, 2024; Jiang et al., 2015, p. 20; Li et al., 2023; Paraiso et al., 2025, 2021; She et al., 2022, p. 202; Xie et al., 2017), and is implicated in mediating the cognitive effects of XN…”
Bi, Y., Song, W., Glymenaki, M., Hu, J., Li, X., Huang, H., Peng, Y., Ni, S., Haonon, O., Liu, Z., et al. (2026) · iMeta · doi:10.1002/imt2.70144 · Cited by 1
Self-citationExpanding bile acid diversity via host and microbial conjugation pathways
Won, T. H., & Schroeder, F. C. (2026) · Natural Product Reports · doi:10.1039/d6np00058d
Increased risk of gallstones with obesity and rapid weight loss
Khalil, M., Ciaula, A. D., Baffy, G., Krawczyk, M. J., & Portincasa, P. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102142
Kuang, S., Wang, J., Jiang, T., Sun, L., Wang, L., Tian, P., Zhai, Q., Zhao, J., Wang, G., & Wang, Z. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.110085
Bile acid signaling in health and disease
Fan, Z., He, M., Liang, T., 张必利, Zhao, N., & Li, P. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00603-4
“On the other hand, intestine-selective FXR inhibition with Gly-MCA amelio-rates obesity, insulin resistance, and hepatic steatosis by suppressing intestinal FXR-dependent ceramide synthesis and counteracting microbiota-driven pro-obesity FXR signaling [220–222].”
Shen, Y., Cai, X., 郑怀军, Zheng, Z., Wu, L., Yuan, M., Jin, X., Ye, D., & Feng, Y. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103036
Zhang, L., Tang, P., Xu, Y., Cheng, C., 朱高峰, & Tang, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02247
Liu, W., Zhang, X., Wang, J., Shi, Y., Yang, H., Li, C., Lan, W., Chen, T., & Tang, Y. (2026) · Vascular Research · doi:10.15302/vr.2026.0002
BindingDB Entry 50018517: Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
BindingDB (2024) · UC San Diego · doi:10.7270/q2ff3xjm
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
BindingDB Entry 50014932: Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.
BindingDB (2023) · UC San Diego · doi:10.7270/q2wm1j9x
Yan, M., Liu, Y., Deng, M., 皮丹丹, Zhu, J., Yu, Q., Huang, C., Ran, Q., Li, W., Zhou, K., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118175
Self-citation
Metadata
- Authors
- Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Pennsylvania State University (US)
- Oregon State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-12-15
- Volume
- 6
- Issue
- 1
- Pages
- 10166-10166
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4682112
- OpenAlex
- W2236340720
- Cited by
- 559
- References
- 58
- Citations by year
- 2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Greater South Information System
- Funders
- Pennsylvania Department of Health
- National Natural Science Foundation of China (31401011, 81200626)
- National Institutes of Health
- National Cancer Institute
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
- MeSH terms
- Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.